SIP
CLDX icon

Stoneridge Investment Partners’s Celldex Therapeutics CLDX Stock Holding History

Stoneridge Investment Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-864
Closed -$37K – 210
2017
Q4 		$37K Hold
864
– – 0.01% 218
2017
Q3 		$37K Hold
864
– – 0.01% 235
2017
Q2 		$32K Sell
864
-1,433
-62% -$63.4K ﹤0.01% 248
2017
Q1 		$124K Sell
2,297
-795
-26% -$41.4K 0.02% 299
2016
Q4 		$164K Hold
3,092
– – 0.02% 274
2016
Q3 		$187K Sell
3,092
-14
-0.5% -$872 0.03% 249
2016
Q2 		$205K Sell
3,106
-7,031
-69% -$446K 0.03% 256
2016
Q1 		$575K Sell
10,137
-1,156
-10% -$130K 0.08% 196
2015
Q4 		$2.66M Sell
11,293
-2,770
-20% -$604K 0.36% 91
2015
Q3 		$2.22M Buy
14,063
+2,174
+18% +$615K 0.31% 101
2015
Q2 		$4.5M Sell
11,889
-2,514
-17% -$998K 0.56% 43
2015
Q1 		$6.02M Buy
14,403
+115
+0.8% +$41.1K 0.71% 37
2014
Q4 		$3.91M Buy
14,288
+2,377
+20% +$591K 0.51% 67
2014
Q3 		$2.32M Sell
11,911
-10
-0.1% -$2.18K 0.34% 97
2014
Q2 		$2.92M Buy
11,921
+8,624
+262% +$1.95M 0.44% 74
2014
Q1 		$874K Buy
3,297
+659
+25% +$252K 0.17% 96
2013
Q4 		$958K Buy
2,638
+1,211
+85% +$467K 0.18% 91
2013
Q3 		$758K Sell
1,427
-765
-35% -$262K 0.17% 100
2013
Q2 		$513K Buy
+2,192
New +$432K 0.12% 102

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stoneridge Investment Partners's CLDX Position: Q1 2018 in Review

Stoneridge Investment Partners sold out of Celldex Therapeutics (CLDX) in Q1 2018, closing a stake of 864 shares — an estimated $37K sold.

Stoneridge Investment Partners first reported a position in CLDX in Q2 2013 and held it in 19 quarters. The position peaked at $6.02M in Q1 2015. 131 funds tracked by Wall St. Rank hold CLDX as of Q1 2018.

  • Stoneridge Investment Partners reported no remaining Celldex Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Stoneridge Investment Partners sold 864 Celldex Therapeutics shares in Q1 2018, an estimated $37K.
  • Stoneridge Investment Partners first reported a position in Celldex Therapeutics in Q2 2013 and held it in 19 quarters.
  • Stoneridge Investment Partners's Celldex Therapeutics position peaked at $6.02M in Q1 2015.
  • 131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2018.

Based on Stoneridge Investment Partners's 13F filing for Q1 2018, filed 27 Apr 2018.